SK pharmteco and Cryoport Partner for Cell and Gene Therapy Logistics and BioServices
NASHVILLE, Tenn. and RANCHO CORDOVA, Calif., Sept. 25, 2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport"), a global leader in...
Pharmaceutical
Vanderbilt University School of Medicine Basic Sciences Adds Carterra’s LSAXT Instrument to Speed Drug and Vaccine Research and Advance Patient Care
The Center for Structural Biology in the School of Medicine Basic Sciences will be a hub of research innovation using Carterra's...
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)Data is confirmed...
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
WOBURN, MA / ACCESSWIRE / September 25, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of...
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
CHICAGO, IL / ACCESSWIRE / September 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Quantum BioPharma to Present at Global Growth and Investment Conference Presented by ArcStone Securities and Investments and Kingswood US
TORONTO, ON / ACCESSWIRE / September 25, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or...
InBrain Pharma to Present Positive Results from Its DIVE-I Phase I/II Clinical Trial for Parkinson’s Disease at the Congress of Parkinson’s Disease and Movement Disorders from September 27 to October 1 in Philadelphia
Lille, September 25, 2024 - InBrain Pharma, a biopharmaceutical company specialized in neurodegenerative diseases, will present the positive results of its...
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
--Data will be presented at the conference in October in MontrealMarlborough, Massachusetts--(Newsfile Corp. - September 25, 2024) - Phio Pharmaceuticals...
Sanner Group acquires Gilero to expand its global medical device offering
Sanner Group acquires Gilero to expand its global medical device offering Acquisition drives Sanner Group’s mission to offer a suite...
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment
Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) --...
GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis
ANKARA, TURKEY / ACCESSWIRE / September 25, 2024 / GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the...
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024
SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the...
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development...
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical...
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many...
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to...
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation...
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose –...
Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders
Elixirgen Therapeutics is currently enrolling patients in its Phase 1/2 trial evaluating EXG-34217 in patients with telomere biology disorders at...